tiprankstipranks
Advertisement
Advertisement

KURA Stock Latest News

Kura Oncology reports first-in-human data from the FIT-001 clinical trial
The FlyKura Oncology reports first-in-human data from the FIT-001 clinical trial
24h ago
KURA
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
PremiumRatings
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
5d ago
KURA
Kura Oncology Earnings Call Signals Early Launch Strength
PremiumCompany Announcements
Kura Oncology Earnings Call Signals Early Launch Strength
7d ago
KURA
Kura Oncology Earnings Call Highlights Comzifty Momentum
PremiumCompany Announcements
Kura Oncology Earnings Call Highlights Comzifty Momentum
13d ago
KURA
Closing Bell Movers: Karman falls over 10% after Q1 earnings miss
PremiumThe Fly
Closing Bell Movers: Karman falls over 10% after Q1 earnings miss
14d ago
AIP
INR
Kura Oncology reports Q1 EPS (83c), consensus (78c)
PremiumThe FlyKura Oncology reports Q1 EPS (83c), consensus (78c)
15d ago
KURA
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
Premium
The Fly
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
15d ago
KURA
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
Premium
Ratings
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
1M ago
KURA
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
PremiumRatings
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
1M ago
KURA
Kura Oncology reports results from ongoing FIT-001 clinical trial
PremiumThe Fly
Kura Oncology reports results from ongoing FIT-001 clinical trial
1M ago
KURA
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
PremiumMarket News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
1M ago
ANGX
IMRX
Kura Oncology initiated with a Buy at Lake Street
PremiumThe Fly
Kura Oncology initiated with a Buy at Lake Street
1M ago
KURA
Syndax assumed with a Buy at Jefferies
PremiumThe FlySyndax assumed with a Buy at Jefferies
2M ago
KURA
SNDX
Kura Oncology price target lowered to $25 from $30 at Mizuho
Premium
The Fly
Kura Oncology price target lowered to $25 from $30 at Mizuho
2M ago
KURA
Kura Oncology price target lowered to $15 from $16 at UBS
Premium
The Fly
Kura Oncology price target lowered to $15 from $16 at UBS
2M ago
KURA
Kura Oncology price target raised to $30 from $29 at BofA
PremiumThe Fly
Kura Oncology price target raised to $30 from $29 at BofA
3M ago
KURA
Kura Oncology price target lowered to $36 from $38 at Wedbush
PremiumThe Fly
Kura Oncology price target lowered to $36 from $38 at Wedbush
3M ago
KURA
Kura Oncology reports inducement grants under Nasdaq listing rule
PremiumThe Fly
Kura Oncology reports inducement grants under Nasdaq listing rule
3M ago
KURA
Kura Oncology Earnings Call Highlights Comzifty Launch
PremiumCompany Announcements
Kura Oncology Earnings Call Highlights Comzifty Launch
3M ago
KURA
Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
PremiumRatingsEarly Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
3M ago
KURA
Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating
Premium
Ratings
Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating
3M ago
KURA
Kura Oncology reports Q4 EPS (92c), consensus (49c)
Premium
The Fly
Kura Oncology reports Q4 EPS (92c), consensus (49c)
3M ago
KURA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >